Clinical investigationsPatient characteristics, care patterns, and outcomes of atrial fibrillation associated hospitalizations in patients with chronic kidney disease and end-stage renal disease
Graphical abstract
Introduction
Atrial fibrillation (AF) is the most common arrhythmia in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD).1 Recent epidemiological studies have shown a strong association between AF and CKD/ESRD.2,3 Patients with CKD/ESRD have a higher thromboembolic risk associated with AF,4, 5, 6 and a higher bleeding risk associated with oral anticoagulation (OAC) compared with patients with a normal renal function.6,7 The 2019 focused update of the 2014 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Rhythm Society (HRS) AF practice guidelines recommends consideration oral anticoagulation (OAC) in patients with CKD/ESRD and moderate-to-high risk of stroke as defined by a CHA2DS2-VASc score ≥2.8 However, there remains significant uncertainty regarding the optimal oral anticoagulation (direct acting OAC versus vitamin K antagonism) clinical effectiveness and bleeding risk associated with OAC in patients with CKD/ESRD.9,10 Clinical decision-making for a rate versus rhythm control approach for AF management in patients with CKD/ESRD is frequently based on an extrapolation of evidence from clinical trials that have traditionally excluded patients with CKD/ESRD.1 Given these uncertainties surrounding a rate versus rhythm control strategy and OAC use for thromboprophylaxis in AF in the setting of CKD/ESRD, it is likely that significant hospital-level practice variation exists in the management of hospitalized AF patients with CKD/ESRD. There is a paucity of real-world data on differences in patient characteristics, care patterns, and outcomes of AF hospitalization for patients with a normal renal function versus those with CKD/ESRD.
There were 3 main objectives in this analysis. First, we sought to describe baseline characteristics, in-hospital care patterns, and differences in discharge characteristics among patients hospitalized with AF stratified by renal function. Second, we sought to describe the association of renal function with in-hospital outcomes. Finally, we sought to ascertain between-hospital variation in utilization of a rhythm control strategy and prescription of OAC at discharge, stratified by renal function.
Section snippets
Study design, setting, and population
We performed a retrospective cohort study of patients ≥18 years hospitalized for a principal diagnosis of atrial fibrillation or atrial flutter (AF). We excluded patients with missing data on eGFR, dialysis history, age, sex, race, medical history, discharge disposition, and rate versus rhythm control strategy. Patients who were discharged against medical advice and those at low-volume centers with <25 AF hospitalizations were also excluded (Supplemental Figure 1).
Data source
We used data from the American
Baseline characteristics
A total of 50,154 patients from 105 hospitals were included in this study. Of these, 62.4% had a normal renal function, 36.0% had CKD, and 1.6% had ESRD. For the overall study cohort, median age was 70 (IQR 61-79) years and 47.3% were women. 83.3% of patients were White while 7.2% were Black. A large majority of patients were covered by some form of insurance while 2.3% were uninsured. Prevalent comorbidities included hypertension (75.0%), diabetes (27.5%), heart failure (25.5%), CVA/TIA
Discussion
In the current study using a large contemporary cohort of AF hospitalizations from a national quality improvement registry, there were several important and noteworthy findings. First, over a third of all patients hospitalized for AF had a diagnosis of CKD or ESRD. Second, while rates of OAC prescription at discharge approached 90% among eligible patients, CKD/ESRD was associated with significantly lower adjusted odds of OAC prescription at discharge compared with patients with a normal renal
Disclosures
This work was supported by the American Heart Association Young Investigator Seed Grant Award, The Get With The Guidelines–AFib (GWTG-AF) program is provided by the American Heart Association. GWTG-AF is sponsored, in part, by Daiiachi Sankyo, Boehringer Ingelheim, and BMS Pfizer.
The authors report the following additional disclosures: JPP receives grants for clinical research from Abbott, American Heart Association, Association for the Advancement of Medical Instrumentation, Bayer, Boston
References (31)
- et al.
Atrial fibrillation and incident end-stage renal disease: The reasons for geographic and racial differences in Stroke (REGARDS) study
Int J Cardiol
(2015) - et al.
Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation
Am J Cardiol
(2014) - et al.
2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation
J Am Coll Cardiol
(2019) - et al.
Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: A meta-analysis of observational studies
Chest
(2016) - et al.
Treatment of atrial fibrillation in patients with chronic kidney disease: is stroke prevention worth the risk?
Chest
(2016) - et al.
Implant success and safety of left atrial appendage occlusion in end stage renal disease patients: Peri-procedural outcomes from an Italian dialysis population
Int J Cardiol
(2018) - et al.
Relation of recurrence of atrial fibrillation after successful cardioversion to renal function
Am J Cardiol
(2010) - et al.
Atrial fibrillation associated hospitalizations in patients with end-stage renal disease in the United States
Heart Rhythm
(2016) - et al.
Chronic kidney disease and arrhythmias: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference
Eur Heart J
(2018) - et al.
Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease
Circulation
(2013)
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
Circulation
Stroke and bleeding in atrial fibrillation with chronic kidney disease
N Engl J Med
Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis
Circulation
Get with the guidelines AFIB: Novel quality improvement registry for hospitalized patients with atrial fibrillation
Circ Cardiovasc Qual Outcomes
Evaluation of the modification of diet in renal disease study equation in a large diverse population
J Am Soc Nephrol
Cited by (1)
The Effect of Humanistic Care Combined with Predictive Nursing on Negative Emotions and Incidence of Cardiovascular Events in Hemodialysis Patients
2022, Computational and Mathematical Methods in Medicine